Title :

Outcome of large B-cell lymphoma patients treated with tafasitamab plus lenalidomide either before or after CAR-T-cells.

Author(s) :

Camus, V. [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
Houot, R. [Auteur]
Centre Hospitalier Universitaire [Rennes]
Brisou, G. [Auteur]
Institut Paoli-Calmettes [IPC]
Tessoulin, B. [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Bailly, S. [Auteur]
Université de Clermont-Ferrand
Sesques, P. [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Decroocq, J. [Auteur]
Institut Cochin [IC UM3 (UMR 8104 / U1016)]
Krzisch, D. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Obéric, L. [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Lemonnier, F. [Auteur]
Hôpital Henri Mondor
Bouabdallah, K. [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Campidelli, A. [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Tounes, L. [Auteur]
Immunochimie des Régulations Cellulaires et des Interactions Virales [Inserm U354/Hôpital Saint-Antoine-APHP]
Abraham, J. [Auteur]
Service d'Hématologie biologique [CHU Limoges]
Herbaux, C. [Auteur]
CHU Montpellier = Montpellier University Hospital
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Damaj, G. [Auteur]
Université de Caen Normandie [UNICAEN]
Guidez, S. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Carras, S. [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Fornecker, L. M. [Auteur]
Institut de Cancérologie de Strasbourg Europe [ICANS]
Choquet, S. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Hermine, O. [Auteur]
Imagine - Institut des maladies génétiques (IHU) [Imagine - U1163]
Paillassa, J. [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Chauchet, A. [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Casasnovas, O. [Auteur]
CHU Dijon
Drieu La Rochelle, L. [Auteur]
CHU Trousseau [Tours]
Castilla-Llorente, C. [Auteur]
Département d'hématologie [Gustave Roussy]
Joris, M. [Auteur]
CHU Amiens-Picardie
Dupont, V. [Auteur]
The Lymphoma Academic Research Organisation [Lyon] [LYSARC]
Marquet, A. [Auteur]
The Lymphoma Academic Research Organisation [Lyon] [LYSARC]
Le Gouill, S. [Auteur]
Institut Curie - Saint Cloud [ICSC]
Jardin, F. [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]

Journal title :

Blood Advances

Abbreviated title :

Blood Adv

Publication date :

2024-08-27

ISSN :

2473-9537

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 CAR T-cell is currently debated. We analyzed large B-cell lymphoma patients in the DESCAR-T registry treated with axi-cel or tisa-cel in ...
Show more >Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 CAR T-cell is currently debated. We analyzed large B-cell lymphoma patients in the DESCAR-T registry treated with axi-cel or tisa-cel in ≥3rd line (L3+) and TAFA-LEN before (n=15, 'TL-pre-CAR-T' set) or directly after (n=52, 'TL-post-CAR-T' set) CAR T-cell. We compared TAFA-LEN v. other treatments using inverse probability weighting in the TL-post-CAR-T set. In the TL-post-CAR-T' set, the median follow-up duration (mFUD) was 7 months, and the median progression-free survival, overall survival and duration of response since the 1st treatment for progression (mPFS2/mOS2/mDOR2) were 3, 4.7 and 8.1 months, respectively. The best overall response rate (bORR) and best complete response rate (bCRR) after TAFA-LEN were 13.5% and 7.7%, respectively. Outcomes were better for patients who relapsed >6 months after CAR T-cell (mPFS2: 5.6 vs. 2 months, p=0.0138; mOS2: not reached vs. 3.8 months, p=0.0034). bORR and bCRR between TAFA-LEN and other treatments were 20.6% vs. 24.9% and 11.6% vs. 15.6%, respectively. Outcomes were similar between TAFA-LEN and other treatments (mPFS2: 2.9 [2-2.6] vs. 2.4 [1.5-4.2] months, p=0.91; mOS2: 3.3 [1.8-6.4] vs. 5.5 [4.4-6.3] months, p=0.06). In an exploratory analysis of the TL-pre-CAR-T set (mFUD since CAR T-cell: 2.8 months), the median TAFA-LEN treatment duration prior to CAR-T was 3.7 months and no patients were reported to become CD19 negative. The bORR, bCRR, 6-month PFS and OS rates after CAR T-cell infusion were 45.5%, 36.4%, 20.1% and 58.2%, respectively. Neither TAFA-LEN nor comparative salvage treatments improved outcomes of patients who relapsed after CAR T-cell.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2024-09-06T21:02:32Z
2024-09-25T08:25:02Z
2024-09-25T08:28:21Z